BACKGROUND Intrapleural fibrinolytics have been used successfully worldwide for the management of complicated pleural effusions and empyema. Bleeding complications are usually mentioned as rare side effects, but there is no clear information in the literature addressing the alarming outcome that might result following the use of alteplase as a fibrinolytic in the management of complicated parap...

Objective: To compare the therapeutic effects of intravenous alteplase thrombolysis, intravenous urokinase thrombolysis and interventional urokinase thrombolysis for acute ischemic stroke. Methods: One hundred and twenty patients of acute ischemic stroke who were treated in our hospital from January 2015 to January 2017 were selected and separated into intravenous alteplase thrombolytic treatme...

Introduction Patients ≥ 80 years of age are increasingly receiving intravenous thrombolysis for acute ischaemic stroke (AIS) despite lack of firm evidence. This systematic review assesses the safety and efficacy of intravenous thrombolysis with alteplase in ≥ 80 versus < 80 year old patients with AIS. Methods The existing literature was systematically analysed for outcome measures of mortality,...

In this article we report on the development, introduction, and maintenance of a policy to promote rational use of thrombolytic drugs by hospital doctors. The work was undertaken within the framework of the voluntarily operated Riverside East drugs guide (formulary) management system (FMS). The policy was introduced in October 1988 and revised in November 1989 to coincide with the launch of the...

OBJECTIVE To examine the efficacy, safety, and the pharmacokinetic profile of a bolus dose administration regimen of alteplase in the treatment of acute myocardial infarction. DESIGN An open pilot study. SETTING District general hospital. PATIENTS 33 suitable consecutive patients presenting within six hours of the onset of symptoms who satisfied the electrocardiographic criteria for acute...

Background and Purpose: There is interest in what happens over time to the thrombus after intravenous alteplase. We study effect of alteplase on structure its impact clinical outcome patients with acute stroke. Methods: Intravenous treated stroke intracranial internal carotid artery or middle cerebral occlusion identified baseline computed tomography angiography follow-up vascular imaging (comp...

COVID-19 is an independent risk factor for pulmonary embolism (PE). Little known about alteplase therapy in this patient group. A retrospective study analyzed 74 patients with PE and acute respiratory distress syndrome (ARDS) due to who were hospitalized the intensive care unit 2021. Patients or without confirmed right heart thrombi (RHT) treated unfractionated heparin alteplase. The mortality ...

Because of high mortality caused by cardiovascular diseases, various fibrinolytic agents with diverse pharmacokinetic and pharmacodynamic properties have been developed. A novel mutated chimeric tissue plasminogen activator (mt-PA) was developed by the removal of first three domains of t-PA, insertion of GHRP sequence and mutation towards resistance to plasminogen activator inhibitor-1 (PAI-1)....

The use of fibrinolytic agents in the early treatment of ST-segment elevation myocardial infarction (STEMI) is known to significantly reduce mortality. Accelerated (“frontloaded”) alteplase is being challenged as the standard of care for pharmacological reperfusion. Alteplase, reteplase, and streptokinase have several limitations. The search for newer agents has focused on developing a fibrinol...

Patients with pulmonary thromboembolism (PE) often decompensate suddenly, and once hemodynamic compromise has developed, mortality is extremely high. Currently, thrombolytic therapy for PE is still controversial. We retrospectively evaluated 34 patients with PE between January 2010 and December 2013 in the Department of Pulmonary Medicine, Medical Park Samsun Hospital, Samsun, Turkey. The demog...